BIAF logo

BIAF
BioAffinity Technologies Inc

3,945
Mkt Cap
$9.85M
Volume
306,694.00
52W High
$15.00
52W Low
$0.693
PE Ratio
-0.14
BIAF Fundamentals
Price
$2.19
Prev Close
$2.49
Open
$2.41
50D MA
$2.50
Beta
1.60
Avg. Volume
1.09M
EPS (Annual)
-$8.66
P/B
1.35
Rev/Employee
$108,104.54
$3.26
Loading...
Loading...
News
all
press releases
bioAffinity Technologies Launches New Study To Expand Use of CyPath Lung Technology for Asthma and COPD Diagnosis and Treatment
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a pilot study with Brooke Army...
Business Wire·4d ago
News Placeholder
More News
News Placeholder
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
Zacks·16d ago
News Placeholder
New Case Study: bioAffinity Technologies CyPath Lung Diagnostic Supports Physicians Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study...
Business Wire·18d ago
News Placeholder
bioAffinity Technologies CyPath Lung to Be Featured at Cleveland Clinic Annual Advances in Early Lung Cancer Detection Symposium April 16
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, announces that its CyPath Lung test will be featured at...
Business Wire·25d ago
News Placeholder
BIAF Stock Gains As CyPath Sales Surge 146% In Q1
The test is capable of identifying lung cancer at Stage 1A, enhancing chances for effective treatment.
Stocktwits·1mo ago
News Placeholder
bioAffinity Technologies CyPath Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath Lung...
Business Wire·1mo ago
News Placeholder
UGRO, TURB, ANNA, EEIQ, BIAF: These Five Stocks Outpaced Big Tech With Massive March Returns
As big tech faltered during sector shifts, share prices of some of the smaller companies surged amid restructuring efforts and key business achievements.
Stocktwits·1mo ago
News Placeholder
What's Going On With bioAffinity Technologies Stock Wednesday?
bioAffinity Technologies Inc (NASDAQ: BIAF) shares trade higher in Wednesday's premarket after announcing a live virtual roundtable for its CyPath Lung test.read more...
Benzinga·1mo ago
News Placeholder
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath Lung into Pulmonary Practice
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced it will host the first of a series of live...
Business Wire·1mo ago
News Placeholder
BIAF Stock Surges 85%, Breaks 200-DMA For The First Time In Nearly A Year – Here’s What’s Driving The Rally
The stock has been on a sharp uptrend, gaining more than 160% over the past week on the back of bullish CyPath Lung estimates.
Stocktwits·1mo ago
<
1
2
...
>

Latest BIAF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.